Medical Science Liaison Memorial Hermann The Woodlands Medical Center Spring, Texas
Disclosure(s):
Brooke Barlow, PharmD: Grifols Shared Services of North America: Employee (any industry) (Ongoing)
Ensuring safe, effective, and timely care for patients with acute ischemic stroke can decrease stroke-related morbidity and mortality. Tenecteplase has emerged as an alternative to alteplase for thrombolytic therapy in patients with acute ischemic stroke. Evidence suggests potential improved outcomes in some patient populations. Scientific evidence, operational logistics, and cost considerations can guide institutional conversations when determining preferred formulary thrombolytic therapy. This session focuses on a multiprofessional approach to implementing an alteplase-to-tenecteplase protocol. Speakers will address the rationale for a fibrinolytic switch, clinical considerations, patient outcomes, and the communication and team-based approach essential to the successful conversion of a high-risk medication. Safety considerations in prescribing, ordering, administration, and monitoring will be covered. This session will use a flipped classroom format. The focus will be on physician and pharmacist roles before, during, and after transition. Speakers will discuss cases to emphasize important considerations during the transition and the key players essential to ensuring success. Speakers will engage audience members to solicit thoughts and allow for questions.
Learning Objectives:
Review the literature surrounding the use of tenecteplase versus alteplase and considerations before switching agents at an institution
Identify key multiprofessional members essential to facilitating and assisting with a transition from alteplase to tenecteplase
Discuss considerations and strategies to ensure a smooth transition in prescribing, ordering, administration, and monitoring of the medication
